| Identification | Back Directory | [Name]
2H-1-Benzopyran-7-ol, 3-(3,5-difluorophenyl)-2-[4-[(1E)-3-[3-(fluoromethyl)-1-azetidinyl]-1-propen-1-yl]phenyl]-4-methyl-, (2S)- | [CAS]
2505067-70-7 | [Synonyms]
Bexirestrant
2H-1-Benzopyran-7-ol, 3-(3,5-difluorophenyl)-2-[4-[(1E)-3-[3-(fluoromethyl)-1-azetidinyl]-1-propen-1-yl]phenyl]-4-methyl-, (2S)- | [Molecular Formula]
C29H26F3NO2 | [MOL File]
2505067-70-7.mol | [Molecular Weight]
477.52 |
| Chemical Properties | Back Directory | [Boiling point ]
614.3±55.0 °C(Predicted) | [density ]
1.265±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
9.41±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Bexirestrant is an orally active ER-α degrader. Bexirestrant can be used for the research of antiestrogen, antineoplastic[1][2]. | [in vivo]
Bexirestrant (50mg/kg; p.o.; 28 days) shows a good efficacy in an MCF-Y537S xenograft[1]. Pharmacokinetic parameters in rat at 50 mg/kg p.o. dose[1]:
| Tmax (h) | Cmax (ng/mL) | AUClast (hr× ng/mL) | AUCinf_obs (hr×ng/mL) | T1/2 (h) | | 4.00 | 343 | 7582 | 9804 | 26 |
| Animal Model: | Female athymic nude mice harboring subcutaneous MCF7-Y537S xenograft[1] | | Dosage: | 50mg/kg | | Administration: | p.o. for 28 days | | Result: | Showed 56% tumor growth inhibition compared to vehicle group after 28 days. |
| [References]
[1] Ranjan Kumar Pal, et al, Selective estrogen receptor degrader. WO2021014386 A1.
[2] WHO Drug Information, Vol. 35, No. 4, 2021. Geneva: World Health Organization; 2022. |
|
|